Sign in
CompletedNo phase

Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

Key facts

Who runs it
Alcon Research
Where
Fort Worth, Jacksonville, Liverpool, Salt Lake City, Torrance, and Tulsa, United StatesSee the 6 sitesAlso in 1 other country, 1 site
Trial code
Status
Completed
People taking part
470 people enrolled
Started
19 Sept 2023
Ended
21 Aug 2026
Type of study
Interventional, 4 groups
Treatments tested
  • Clareon Vivity IOL - Non Toric
  • Clareon Vivity IOL - Toric
  • Clareon PanOptix Trifocal IOL - Non Toric
  • Clareon PanOptix Trifocal IOL - Toric
Record updated
2 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Subject or legally authorized representative must be able to understand and sign an approved Informed Consent Form
  • Subject must have had bilateral implantation of Clareon Vivity, Clareon Vivity Toric, Clareon PanOptix, or Clareon PanOptix Toric IOLs between 3-6 months prior to enrollment
  • Subject must have a documented medical history and required pre-operative baseline information available for retrospective data collection
  • Other protocol-defined inclusion criteria may apply

Who cannot take part

  • Subject is currently participating in another investigational drug or device study
  • Subject has had corneal refractive surgery after Clareon Vivity, Clareon Vivity Toric, Clareon PanOptix, or Clareon PanOptix Toric IOL implantation
  • Subject is pregnant at the time of enrollment
  • Other protocol-defined exclusion criteria may apply

Where in United States

Also in 1 other country, 1 site

  • Chu Eye InstituteFort Worth, United States
  • Levenson Eye AssociatesJacksonville, United States
  • Eye Surgeons of CNYLiverpool, United States
  • The Eye Institute of UtahSalt Lake City, United States
  • Wolstan & Goldberg Eye AssociatesTorrance, United States
  • Tulsa OphthalmologyTulsa, United States

About the trial

What the trial wants to find out

The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.

The 4 groups in the trial

  • Clareon Vivity IOL - Non ToricTreatment being tested

    Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon Vivity IOL.

  • Clareon Vivity IOL - ToricTreatment being tested

    Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon Vivity IOL.

  • Clareon PanOptix IOL - Non ToricTreatment being tested

    Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon PanOptix IOL.

    Treatment: Clareon PanOptix Trifocal IOL - Non Toric

  • Clareon PanOptix IOL - ToricTreatment being tested

    Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon PanOptix IOL.

    Treatment: Clareon PanOptix Trifocal IOL - Toric

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Long-term Evaluation of Safety and Performance of Clareon Presbyopia-Correcting Intraocular Lenses (IOLs)
Record updated
2 September 2026